| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX009 (ip) | median survival time | saline | 25.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 50.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 100.0 mg/kg/injection | 181.0 | Antitumor endpoint evaluated on day 60; 08/09 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 200.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline | 400.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 09/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | suspension in saline | 12.5 mg/kg/injection | 113.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | suspension in saline | 25.0 mg/kg/injection | 125.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | suspension in saline | 50.0 mg/kg/injection | 167.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | suspension in saline | 100.0 mg/kg/injection | 206.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | suspension in saline | 200.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 60; 10/10 animals surviving on day 5 |